ArticleCancer chemotherapy and pharmacology2018

Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer.

Nicolas Martin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.